基于结构的人工智能辅助设计用于癌症治疗的MYC向降解药物
Donghua Liu1, Yize Jiang1, Bohan Ma1
1Department of Urology, The First Affiliated Hospital, Xi'an Jiaotong University, Xi'an, China.
Biochemical and biophysical research communications
|April 27, 2025
概括
研究人员开发了Se-MYC-LYSO,这是一种针对MYCcoprotein的新药. 这种创新药物有效降解MYC,抑制癌细胞生长,并诱导细胞亡,提供了一种新的癌症治疗策略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药物发现 药物发现 药物发现
背景情况:
- MYC蛋白是一种关键的coprotein,涉及到许多癌症.
- 尽管其已知的作用,开发有效的MYC向药物一直是具有挑战性的.
- 准MYC降解是一个有前途的治疗途径.
研究的目的:
- 设计和开发一种针对MYC/MAX二聚体的新型抑制剂.
- 设计一种针对MYC的降解药物,其中包含一个伴侣介导的自信号 (MYC-LYSO).
- 使用纳米输送 (Se-MYC-LYSO) 制备一个增强的MYC降解剂.
主要方法:
- 利用基于MYC/MAX二元结构的人工智能辅助类药物设计.
- 整合了一个伴侣介导的自信号来创建MYC-LYSO.
- 使用纳米用于药物输送,以制备Se-MYC-LYSO.
主要成果:
- 在癌细胞中,Se-MYC-LYSO有效诱导了MYC降解.
- 该药物显著抑制了瘤细胞增殖.
- Se-MYC-LYSO促进了癌细胞亡,其有效性取决于自途径.
结论:
- Se-MYC-LYSO是一种强大的MYC降解剂,在癌症中具有治疗潜力.
- 这项研究强调了自途径在调解药物的疗效方面的重要性.
- 这项工作提供了一个新的策略,通过有针对性的降解来准MYC在癌症治疗中.
相关概念视频
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Drugs that Destabilize Microtubules
1.9K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
1.9K
Protein Networks
3.9K
An organism can have thousands of different proteins, and these proteins must cooperate to ensure the health of an organism. Proteins bind to other proteins and form complexes to carry out their functions. Many proteins interact with multiple other proteins creating a complex network of protein interactions.
These interactions can be represented through maps depicting protein-protein interaction networks, represented as nodes and edges. Nodes are circles that are representative of a protein,...
These interactions can be represented through maps depicting protein-protein interaction networks, represented as nodes and edges. Nodes are circles that are representative of a protein,...
3.9K
Treatment Resistant Cancers
3.2K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.2K
M-Cdk Drives Transition Into Mitosis
5.5K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.5K


